Archived explainer. For the current picture see today's MAZE page.
MAZE THERAPEUTICS IN (MAZE) is down -5.24% in the latest session. Our newswire has captured 1 story on MAZE across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
MAZE stock is down 5.24% at $28.03 in morning trading after a sharp intraday pullback and a recent string of mixed earnings reports. The stock opened at $29.58 but quickly declined to a session low of $27.70 before stabilizing slightly. The sell-off comes amid continued unprofitability and heavy insider selling in recent weeks.
Maze Therapeutics is trading lower despite a recent $150 million licensing deal and a cash position of $494.9 million that extends through 2029. The company remains pre-revenue and has reported negative earnings in recent quarters. Second-quarter earnings of $(0.76) per share missed estimates, while first-quarter results beat expectations. The mixed earnings performance has created uncertainty for investors. Additionally, several insiders, including the CEO and senior executives, have sold shares in the past month, totaling $4.7 million in transactions. These developments have contributed to the stock’s downward momentum.
The stock’s intraday session has been volatile, with volume so far at 0.1 million shares, which is 0.1x the 3-month average. The stock is trading within its 52-week range of $13.28 to $53.65 but is significantly below its 52-week high. The company has a market cap of $1.7 billion and reported a revenue increase of 700% in the trailing twelve months, though it remains unprofitable with an EPS of -2.52. The recent insider selling and earnings volatility suggest ongoing pressure on the stock.
The company is not currently scheduled to report earnings in the near term. Investors should monitor coverage breadth and any new developments regarding its kidney disease assets, which have drawn attention as a potential growth driver.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
With $494.9m in cash extending into 2029 and a recent $150m licensing deal, Maze Therapeutics is well-funded but remains pre-revenue. Click for more on MAZEE.
More on MAZE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier MAZE move explainers: 2026-08-27